Viola Biberacher1, Paul Schmidt2, Rebecca C Selter3, Verena Pernpeinter3, Markus C Kowarik4, Benjamin Knier3, Dorothea Buck3, Muna-Miriam Hoshi3, Thomas Korn4, Achim Berthele3, Jan S Kirschke5, Claus Zimmer5, Bernhard Hemmer4, Mark Mühlau1. 1. Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany/Neuroimaging Center, Technische Universität München, Munich, Germany. 2. Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany/Neuroimaging Center, Technische Universität München, Munich, Germany/Department of Statistics, Ludwig-Maximilians-Universität München, Munich, Germany. 3. Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 4. Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany/Munich Cluster for Systems Neurology (SyNergy), Ludwig-Maximilians-Universität München, Munich, Germany. 5. Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Abstract
BACKGROUND: Damage of different brain structures has been related to fatigue. Alternatively, functional alterations of central nervous system (CNS) cells by the inflammatory milieu within the CNS may be responsible for the development of fatigue. AIM: To investigate the effect of structural brain damage and inflammatory cerebrospinal fluid (CSF) changes on fatigue in multiple sclerosis (MS). METHODS: We determined the association of different clinical, CSF and magnetic resonance imaging (MRI) parameters with prevalence and severity of fatigue, as measured by the Fatigue Scale for Motor and Cognitive Functions in 68 early MS patients (discovery cohort). We validated our findings in two MS cohorts: the MRI validation cohort ( N = 233) for the clinical and MRI parameters, and the CSF validation cohort ( N = 81) for the clinical and CSF parameters. RESULTS: Fatigue was associated with clinical disability. Fatigue did not correlate with any CSF parameter but correlated negatively with total and cortical grey matter volume. However, when controlling for Expanded Disability Status Scale (EDSS) in a multivariate model, these associations lost significance. CONCLUSION: Disability and disease duration best explain fatigue severity but none of the tested MRI or CSF parameter was reliably associated with fatigue.
BACKGROUND: Damage of different brain structures has been related to fatigue. Alternatively, functional alterations of central nervous system (CNS) cells by the inflammatory milieu within the CNS may be responsible for the development of fatigue. AIM: To investigate the effect of structural brain damage and inflammatory cerebrospinal fluid (CSF) changes on fatigue in multiple sclerosis (MS). METHODS: We determined the association of different clinical, CSF and magnetic resonance imaging (MRI) parameters with prevalence and severity of fatigue, as measured by the Fatigue Scale for Motor and Cognitive Functions in 68 early MS patients (discovery cohort). We validated our findings in two MS cohorts: the MRI validation cohort ( N = 233) for the clinical and MRI parameters, and the CSF validation cohort ( N = 81) for the clinical and CSF parameters. RESULTS:Fatigue was associated with clinical disability. Fatigue did not correlate with any CSF parameter but correlated negatively with total and cortical grey matter volume. However, when controlling for Expanded Disability Status Scale (EDSS) in a multivariate model, these associations lost significance. CONCLUSION: Disability and disease duration best explain fatigue severity but none of the tested MRI or CSF parameter was reliably associated with fatigue.
Authors: Aikaterini Christogianni; Richard Bibb; Scott L Davis; Ollie Jay; Michael Barnett; Nikos Evangelou; Davide Filingeri Journal: Temperature (Austin) Date: 2018-09-05
Authors: Christina Engl; Laura Tiemann; Sophia Grahl; Matthias Bussas; Paul Schmidt; Viola Pongratz; Achim Berthele; Annkathrin Beer; Christian Gaser; Jan S Kirschke; Claus Zimmer; Bernhard Hemmer; Mark Mühlau Journal: J Neurol Date: 2020-04-23 Impact factor: 4.849
Authors: Solveig K Hammonds; Maria B Lauvsnes; Ingvild Dalen; Mona K Beyer; Kathinka D Kurz; Ole J Greve; Katrine B Norheim; Roald Omdal Journal: Rheumatol Adv Pract Date: 2017-10-17
Authors: Daniel Drebinger; Ludwig Rasche; Daniel Kroneberg; Patrik Althoff; Judith Bellmann-Strobl; Martin Weygandt; Friedemann Paul; Alexander U Brandt; Tanja Schmitz-Hübsch Journal: Front Neurol Date: 2020-04-15 Impact factor: 4.003